JPWO2021006267A1 - - Google Patents
Info
- Publication number
- JPWO2021006267A1 JPWO2021006267A1 JP2021530700A JP2021530700A JPWO2021006267A1 JP WO2021006267 A1 JPWO2021006267 A1 JP WO2021006267A1 JP 2021530700 A JP2021530700 A JP 2021530700A JP 2021530700 A JP2021530700 A JP 2021530700A JP WO2021006267 A1 JPWO2021006267 A1 JP WO2021006267A1
- Authority
- JP
- Japan
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2019127252 | 2019-07-08 | ||
PCT/JP2020/026541 WO2021006267A1 (ja) | 2019-07-08 | 2020-07-07 | ピラゾール誘導体の塩及びピラゾール誘導体の製剤 |
Publications (1)
Publication Number | Publication Date |
---|---|
JPWO2021006267A1 true JPWO2021006267A1 (enrdf_load_stackoverflow) | 2021-01-14 |
Family
ID=74115288
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021530700A Pending JPWO2021006267A1 (enrdf_load_stackoverflow) | 2019-07-08 | 2020-07-07 |
Country Status (3)
Country | Link |
---|---|
JP (1) | JPWO2021006267A1 (enrdf_load_stackoverflow) |
TW (1) | TW202116752A (enrdf_load_stackoverflow) |
WO (1) | WO2021006267A1 (enrdf_load_stackoverflow) |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012141228A1 (ja) * | 2011-04-11 | 2012-10-18 | 株式会社ファルマエイト | 新規ピラゾール誘導体 |
WO2014057772A1 (ja) * | 2012-10-10 | 2014-04-17 | 株式会社ファルマエイト | 新規ピラゾール誘導体 |
JP2014530875A (ja) * | 2011-10-21 | 2014-11-20 | シーチェイドファーマシューティカルズ,インコーポレーテッド | 医薬組成物及びそれらの使用 |
JP2015500306A (ja) * | 2011-12-13 | 2015-01-05 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | 高融点疎水性化合物のバイオアベイラビリティが向上した薬学的組成物 |
WO2016140219A1 (ja) * | 2015-03-02 | 2016-09-09 | 武田薬品工業株式会社 | ナノ共結晶を含有する懸濁液または組成物およびこれらの製造方法 |
JP2017500332A (ja) * | 2013-12-23 | 2017-01-05 | ラボラトリオス・デル・ドクトル・エステベ・ソシエダッド・アノニマ | 経口医薬組成物 |
JP2017503866A (ja) * | 2014-12-23 | 2017-02-02 | ハンミ ファーム. シーオー., エルティーディー. | デュタステリドを含む自己乳化型薬物送達システムのための組成物 |
-
2020
- 2020-07-07 WO PCT/JP2020/026541 patent/WO2021006267A1/ja active Application Filing
- 2020-07-07 JP JP2021530700A patent/JPWO2021006267A1/ja active Pending
- 2020-07-08 TW TW109123069A patent/TW202116752A/zh unknown
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012141228A1 (ja) * | 2011-04-11 | 2012-10-18 | 株式会社ファルマエイト | 新規ピラゾール誘導体 |
JP2014530875A (ja) * | 2011-10-21 | 2014-11-20 | シーチェイドファーマシューティカルズ,インコーポレーテッド | 医薬組成物及びそれらの使用 |
JP2015500306A (ja) * | 2011-12-13 | 2015-01-05 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | 高融点疎水性化合物のバイオアベイラビリティが向上した薬学的組成物 |
WO2014057772A1 (ja) * | 2012-10-10 | 2014-04-17 | 株式会社ファルマエイト | 新規ピラゾール誘導体 |
JP2017500332A (ja) * | 2013-12-23 | 2017-01-05 | ラボラトリオス・デル・ドクトル・エステベ・ソシエダッド・アノニマ | 経口医薬組成物 |
JP2017503866A (ja) * | 2014-12-23 | 2017-02-02 | ハンミ ファーム. シーオー., エルティーディー. | デュタステリドを含む自己乳化型薬物送達システムのための組成物 |
WO2016140219A1 (ja) * | 2015-03-02 | 2016-09-09 | 武田薬品工業株式会社 | ナノ共結晶を含有する懸濁液または組成物およびこれらの製造方法 |
Also Published As
Publication number | Publication date |
---|---|
WO2021006267A1 (ja) | 2021-01-14 |
TW202116752A (zh) | 2021-05-01 |
Similar Documents
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20220107 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20230216 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240206 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20240404 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20240730 |